Price$5.70+2.04 (+55.74%)
2026-03-112026-06-12
News · 26 weeks42+250%
2025-12-142026-06-07
Mix3190d
- SEC Filings12(39%)
- Other9(29%)
- Insider9(29%)
- Leadership1(3%)
Latest news
25 items- INSIDERSEC Form 4 filed by Director Dewhurst Martin William4 - Turn Therapeutics Inc. (0002023016) (Issuer)
- INSIDERSEC Form 4 filed by Director Gengos Andrew4 - Turn Therapeutics Inc. (0002023016) (Issuer)
- INSIDERSEC Form 4 filed by Director Golden Arthur F4 - Turn Therapeutics Inc. (0002023016) (Issuer)
- INSIDERSEC Form 4 filed by Director Kester Kent Edward4 - Turn Therapeutics Inc. (0002023016) (Issuer)
- SECTurn Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure8-K - Turn Therapeutics Inc. (0002023016) (Filer)
- INSIDERChief Executive Officer Burnam Bradley Evan received a gift of 600,000 shares and gifted 600,000 shares (SEC Form 4)4 - Turn Therapeutics Inc. (0002023016) (Issuer)
- SECTurn Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure8-K - Turn Therapeutics Inc. (0002023016) (Filer)
- PRTurn Therapeutics Reports Interim Analysis Findings and Adaptive Optimization Strategy from Phase 2 GX-03 Trial in Moderate-to-Severe Atopic Dermatitis92.6% of GX-03-treated subjects achieved a 50% reduction in eczema severity in 4 weeks (EASI-50); 70.4% achieved a 75% reduction in 4 weeks (EASI-75); 44.4% achieved a 90% reduction in 4 weeks (EASI-90); and 51.9% achieved a 90% reduction in 8 weeks (EASI-90) Interim analysis informed refinement of enrollment criteria, endpoint hierarchy, and overall trial optimization strategy No treatment-related serious adverse events observed in either treatment group; no treatment-related tolerability issues or discontinuations reported during the interim analysis period Turn Therapeutics Inc. (NASDAQ:TTRX), a clinical-stage biotechnology company developing targeted, localized therapies for infla
- SECTurn Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure8-K - Turn Therapeutics Inc. (0002023016) (Filer)
- PRTurn Therapeutics Announces Peer-Reviewed Publication in Journal of Dermatological Treatment Highlighting GX-03 Activity in IL-36 Associated Inflammatory ModelStudy demonstrates statistically significant reduction in disease severity in a murine dermatitis model characterized by IL-36 expression First in a planned series of peer-reviewed publications exploring the scientific rationale and non-systemic mechanism underlying GX-03, currently in Phase 2 evaluation for moderate-to-severe atopic dermatitis Turn Therapeutics Inc. (NASDAQ:TTRX), a clinical-stage biotechnology company focused on developing localized therapies for inflammatory and infectious skin diseases, today announced the publication of a peer-reviewed research article in the Journal of Dermatological Treatment evaluating the effects of its lead program, GX-03, in an IL-36–assoc
- SECTurn Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure8-K - Turn Therapeutics Inc. (0002023016) (Filer)
- PRTurn Therapeutics to Present at Jefferies Global Healthcare Conference 2026Turn Therapeutics Inc. (NASDAQ:TTRX), a clinical-stage biotechnology company developing targeted, localized therapies for inflammatory skin diseases, today announced that Bradley Burnam, Chief Executive Officer, will present at the Jefferies Global Healthcare Conference in New York City as follows: Date: June 4, 2026 Time: 9:55 AM – 10:25 AM EDT A live webcast of the presentation may be accessed on the Investors section of the Turn Therapeutics website at https://ir.turntherapeutics.com/news-events/presentations. A replay of the webcast will be available on the Turn Therapeutics website for approximately six months following the presentation. About Turn Therapeutics Turn Therapeutic
- SECTurn Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure8-K - Turn Therapeutics Inc. (0002023016) (Filer)
- PRTurn Therapeutics Appoints Physician-Scientist and Former FDA Commissioner, Dr. Stephen M. Hahn, as Executive Clinical and Regulatory LeadDr. Hahn Brings Unparalleled Clinical and Regulatory Expertise to Support Advancement of GX-03 for Moderate-to-Severe Atopic Dermatitis and Pipeline Indications Turn Therapeutics Inc. (NASDAQ:TTRX), a clinical-stage biotechnology company developing targeted, localized therapies for inflammatory skin diseases, today announced the appointment of Stephen M. Hahn, M.D., former Commissioner of the U.S. Food and Drug Administration (FDA), to oversee the clinical and regulatory strategy for GX-03, the Company's investigational topical therapy currently in a Phase 2 clinical trial for moderate-to-severe atopic dermatitis (eczema). "Patients with inflammatory skin diseases still lack adequate
- SECSEC Form C-TR filed by Turn Therapeutics Inc.C-TR - Turn Therapeutics Inc. (0002023016) (Filer)
- SECSEC Form 10-Q filed by Turn Therapeutics Inc.10-Q - Turn Therapeutics Inc. (0002023016) (Filer)
- SECTurn Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition8-K - Turn Therapeutics Inc. (0002023016) (Filer)
- PRTurn Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate UpdatesPhase 2 Trial for GX-03 in Moderate-to-Severe Atopic Dermatitis (AD) on Track, Topline Results Expected Mid-2026 Initial Tranche of $7 Million in Growth Capital has been Funded by Avenue Capital Group Turn Therapeutics Inc. (NASDAQ:TTRX), a clinical-stage biotechnology company developing targeted inflammatory and immunological therapies for dermatologic conditions, today reported financial results for the three months ended March 31, 2026, and provided corporate updates. "The first quarter of 2026 materially strengthened Turn Therapeutics both operationally and financially," said Bradley Burnam, Chief Executive Officer of Turn Therapeutics. "With the Avenue Capital facility now in pla
- INSIDERSEC Form 4 filed by Burnam Bradley Evan4 - Turn Therapeutics Inc. (0002023016) (Issuer)
- INSIDERSEC Form 4 filed by Golden Arthur F4 - Turn Therapeutics Inc. (0002023016) (Issuer)
- INSIDERSEC Form 4 filed by Burnam Bradley Evan4 - Turn Therapeutics Inc. (0002023016) (Issuer)
- INSIDERSEC Form 4 filed by Chaudhary Zuraiz4 - Turn Therapeutics Inc. (0002023016) (Issuer)
- SECSEC Form EFFECT filed by Turn Therapeutics Inc.EFFECT - Turn Therapeutics Inc. (0002023016) (Filer)
- SECSEC Form EFFECT filed by Turn Therapeutics Inc.EFFECT - Turn Therapeutics Inc. (0002023016) (Filer)
- SECSEC Form POS AM filed by Turn Therapeutics Inc.POS AM - Turn Therapeutics Inc. (0002023016) (Filer)
TTRX FAQ
5 questionsWhere does TTRX stock trade?
Turn Therapeutics Inc. (TTRX) is listed on NASDAQ.What sector and industry is TTRX in?
Turn Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about TTRX?
Turn Therapeutics Inc. has had 1 recent analyst action on file. The most recent action was from D. Boral Capital: Buy with a $800.00 price target on 2025-12-29. Recent price targets cluster around $800.00.What companies are similar to TTRX?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), AZN (AstraZeneca PLC), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare TTRX side-by-side with any of them on Quantisnow.How can I track TTRX on Quantisnow?
Quantisnow aggregates Turn Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow TTRX to receive live email and push alerts on every new disclosure.